TR-57

1 paper1 finding

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Animals1

Outcomes

Triple-negative breast cancer

downin mice1

1 study

TR-57 prevents triple-negative breast cancer in mice.
“This response was reproduced in vivo wherein senescent 4T1-Luc cells did not develop tumors following injection into mice.”
Animalsfollowing injection of TR-57-induced senescent 4T1-Luc cells
Small Molecule Activators of the Mitochondrial Protease ClpP Induce Senescence in Triple-Negative Breast Cancer Cells and Sensitize Cells to the Bcl-2 Inhibitor Venetoclax
Research square19 Nov 2025Preprint

Latest

1 in 12 months

Research Square3 Dec

Small Molecule Activators of the Mitochondrial Protease ClpP Induce Senescence in Triple-Negative Breast Cancer Cells and Sensitize Cells to the Bcl-2 Inhibitor Venetoclax

Preprint: experiments in miceInterventions

Paper

TR-57

Outcomes

Latest

Small Molecule Activators of the Mitochondrial Protease ClpP Induce Senescence in Triple-Negative Breast Cancer Cells and Sensitize Cells to the Bcl-2 Inhibitor Venetoclax

Related